KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024

KalVista Pharmaceuticals, Inc.

2024-Q2 EPS reported -$1.54

Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.
Received Orphan Drug Status from Switzerland for sebetralstat, providing 15-year market protection.
Net loss of $27.7M ($0.80/share) for Q2 FY24 vs. $22.3M ($0.90/share) year ago; revenue nil.
Cash, equivalents and marketable securities $103.2M at Oct 31, 2023, down from $149.4M at Apr 30, 2023.
R&D expenses $19.1M; G&A expenses $10.7M, both up YoY due to trial costs and commercial build-out.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

KalVista Pharmaceuticals, Inc. reported the three months ended October 31, 2023 results: revenue No revenue was recognized, net income Net loss was $27.7 million, EPS $(0.80) per weighted average basic and diluted share.

Period: the three months ended October 31, 2023
Revenue: No revenue was recognized
Net income: Net loss was $27.7 million
EPS: $(0.80) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

On December 7, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2023.

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-068816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.